ATE193020T1 - Verfahren zur herstellung von immunoglobulin g konzentrat - Google Patents

Verfahren zur herstellung von immunoglobulin g konzentrat

Info

Publication number
ATE193020T1
ATE193020T1 AT94918916T AT94918916T ATE193020T1 AT E193020 T1 ATE193020 T1 AT E193020T1 AT 94918916 T AT94918916 T AT 94918916T AT 94918916 T AT94918916 T AT 94918916T AT E193020 T1 ATE193020 T1 AT E193020T1
Authority
AT
Austria
Prior art keywords
concentrate
pct
immunoglobulin
sec
date
Prior art date
Application number
AT94918916T
Other languages
English (en)
Inventor
Miryana Burnouf
Dominique Dernis
Patrick Bonneel
Thierry Burnouf
Original Assignee
Aetsrn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aetsrn filed Critical Aetsrn
Application granted granted Critical
Publication of ATE193020T1 publication Critical patent/ATE193020T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94918916T 1993-06-14 1994-06-13 Verfahren zur herstellung von immunoglobulin g konzentrat ATE193020T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9307128A FR2706466B1 (fr) 1993-06-14 1993-06-14 Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
PCT/FR1994/000699 WO1994029334A1 (fr) 1993-06-14 1994-06-13 Concentre d'immunoglobulines g a usage therapeutique et procede de production dudit concentre

Publications (1)

Publication Number Publication Date
ATE193020T1 true ATE193020T1 (de) 2000-06-15

Family

ID=9448094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94918916T ATE193020T1 (de) 1993-06-14 1994-06-13 Verfahren zur herstellung von immunoglobulin g konzentrat

Country Status (16)

Country Link
US (1) US6069236A (de)
EP (1) EP0703922B1 (de)
JP (1) JP4218980B2 (de)
AT (1) ATE193020T1 (de)
AU (1) AU7002394A (de)
BR (1) BR9406814A (de)
CA (1) CA2165203C (de)
CZ (1) CZ287186B6 (de)
DE (1) DE69424545T2 (de)
DK (1) DK0703922T3 (de)
ES (1) ES2148332T3 (de)
FR (1) FR2706466B1 (de)
GR (1) GR3034177T3 (de)
HU (1) HU218463B (de)
PT (1) PT703922E (de)
WO (1) WO1994029334A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2272870T3 (da) * 1998-06-09 2013-08-05 Csl Behring Ag Fremgangsmåde til fremstilling af immunoglobuliner med henblik på intravenøs indgivelse og andre immunoglobulin-lignende produkter.
ES2229784T3 (es) * 1998-06-09 2005-04-16 Statens Serum Institut Proceso de produccion de inmunoglobulinas para administracion intravenosa y otros productos de inmunoglobulina.
US6962700B1 (en) * 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP1532983A1 (de) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulinpräparationen mit erhöhter Stabilität
TWI320788B (en) * 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
WO2007136327A1 (en) * 2006-05-22 2007-11-29 Ge Healthcare Bio-Sciences Ab A method of producing igg
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
PT2291654T (pt) 2008-05-28 2018-06-15 Prothera Biologics Inc Preparação e composição de proteínas inibidoras de interalfa do sangue
FR2939667B1 (fr) 2008-12-17 2012-01-27 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo
BRPI1012082B1 (pt) 2009-05-27 2022-08-16 Takeda Pharmaceutical Company Limited Método para preparar uma composição de igg concentrada a partir de plasma
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
HRP20160530T1 (hr) 2009-09-17 2016-07-29 Baxalta Incorporated Stabilna ko-formulacija hijaluronidaze i imunoglobulina, te postupci njezine uporabe
IT1397061B1 (it) 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
CA2788863C (en) 2010-02-04 2020-07-07 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
KR20130124507A (ko) 2010-11-16 2013-11-14 옥타파마 아게 응고 인자 ＦＸＩ 및 ＦＸＩａ를 함유한 용액으로부터 ＦＸＩ 및 ＦＸＩａ를 감소시키고 및/또는 제거하는 방법
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
ES2647925T3 (es) 2011-05-12 2017-12-27 Csl Behring Gmbh Métodos para reducir los eventos adversos causados por preparados farmacéuticos que comprenden proteínas derivadas del plasma
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
MX349005B (es) 2011-08-26 2017-07-06 Baxalta Inc Metodo para reducir el potencial tromboembolico de una composicion de inmunoglobulina derivada de plasma.
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
EA201892521A1 (ru) 2012-02-29 2019-07-31 Баксалта Инкорпорейтид РЕМИЕЛИНИЗАЦИЯ ПЕРИФЕРИЧЕСКИХ НЕРВОВ, СТИМУЛИРОВАННАЯ IgG
EP2636684A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Vorbeugung von Infektionen
RU2644240C2 (ru) 2012-03-09 2018-02-08 Цсл Беринг Аг Композиции, содержащие секреторноподобные иммуноглобулины
EP2636681A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Verfahren zur Anreicherung von IgA
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
KR20160029840A (ko) * 2013-07-05 2016-03-15 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 친화성 크로마토그래피 매트릭스
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
US10287315B2 (en) * 2014-03-11 2019-05-14 Green Cross Holdings Corporation Method for purifying immunoglobulin
FR3018450B1 (fr) 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines
US9556253B2 (en) * 2014-12-02 2017-01-31 Hemarus Therapeutics Limited Process for increased yield of immunoglobulin from human plasma
MX388043B (es) 2014-12-03 2025-03-19 Csl Behring Ag Producto farmacéutico con estabilidad incrementada que comprende inmunoglobulinas.
CA3036553A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
FR3064484A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition d'immunoglobulines utiles pour traiter des infections virales
FR3064486A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Prevention d'une infection par le virus respiratoire syncytial dans les voies respiratoires superieures
FR3064485A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Traitement d'une infection par le virus respiratoire syncytial
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
CA3173539A1 (en) 2020-03-31 2021-10-07 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CA3203540A1 (en) 2020-12-28 2022-07-07 Eugene ZURLO Systems and methods for process scale isolation of immunoglobulin g
CA3236213A1 (en) 2021-10-27 2023-05-04 Eugene ZURLO Compositions and methods for isolating proteins
EP4689667A1 (de) * 2023-03-29 2026-02-11 CSL Behring AG Verfahren zur identifizierung von mit nebenwirkungen assoziiertem immunglobulin
WO2025068923A2 (en) 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7511055A (nl) * 1975-09-19 1977-03-22 Leuven Res & Dev Vzw Trombosetest.
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
ES8203612A1 (es) * 1981-06-04 1982-04-01 Landerlan Sa Lab Procedimiento de preparacion de imuno globulina g nativa li-bre de actividad anticomplementaria
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US4806346A (en) * 1986-12-16 1989-02-21 American Home Products Corporation Method for isolation of antigen specific immunoglobulin
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
DE4118912C1 (de) * 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
HUT74272A (en) 1996-11-28
FR2706466B1 (fr) 1995-08-25
HU9503557D0 (en) 1996-02-28
CA2165203A1 (fr) 1994-12-22
CA2165203C (fr) 2009-08-18
JPH09500369A (ja) 1997-01-14
BR9406814A (pt) 2000-05-30
EP0703922B1 (de) 2000-05-17
US6069236A (en) 2000-05-30
HU218463B (hu) 2000-09-28
EP0703922A1 (de) 1996-04-03
PT703922E (pt) 2000-11-30
CZ328795A3 (en) 1996-07-17
ES2148332T3 (es) 2000-10-16
JP4218980B2 (ja) 2009-02-04
DE69424545D1 (de) 2000-06-21
WO1994029334A1 (fr) 1994-12-22
GR3034177T3 (en) 2000-11-30
CZ287186B6 (en) 2000-10-11
DE69424545T2 (de) 2001-01-18
FR2706466A1 (fr) 1994-12-23
AU7002394A (en) 1995-01-03
DK0703922T3 (da) 2000-11-13

Similar Documents

Publication Publication Date Title
DE69424545D1 (de) Verfahren zur herstellung von immunoglobulin g konzentrat
DE59305526D1 (de) Verfahren zur herstellung von olefinen
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
ATE288447T1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
ATE213252T1 (de) Verfahren zur herstellung eines inter-alpha- trypsin inhibitor konzentrats mit therapeutischer anwendung und so erhaltenes konzentrat
ATE232854T1 (de) Verfahren zur herstellung von 9-desoxotaxanen
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE169641T1 (de) Verfahren zur herstellung von stärkeabbauprodukten
ATE174601T1 (de) Verfahren zur herstellung von bisnoraldehyden aus bisnoralkohol
DE69627319D1 (de) Herstellung von immunglobulin
ATE218131T1 (de) Verfahren zur herstellung von mono-n- substituierten tetraazamakrocyclen
FI973469A0 (fi) Menetelmä tekijän IX valmistamiseksi biologisista lähteistä
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE191457T1 (de) Verfahren zur herstellung von einem bicyclohexanderivat
ATE152722T1 (de) Verfahren zur herstellung von 9-(2-hydroxy)- ethoxy-guanin
EP0711159A4 (de) Verfahren und zusammensetzungen zur behandlung von asthma, arthereosklerose und entzuendlichen erkrankungen unter verwendung von optisch reinem (-)-zilenton
ATE171620T1 (de) Verwendung von verzweigtkettigen aminosäuren zur herstellung eines arzneimittels zur behandlung von tardiver dyskinesia
ATE185349T1 (de) Verfahren zur herstellung von dolastatin 15 und deren zwischenprodukten
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE210665T1 (de) Zwischenprodukte und verfahren zur herstellung von 5,6-dihydropyrrolo(2,3-d)pyrimidinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner